

PRECEPTORSHIP PROGRAMME

Colorectal Cancer

Multidisciplinary management, standards
of care and future perspectives

LUGANO
SWITZERLAND

15-16 NOVEMBER 2019

Co-Chairs

Erika Martinelli, IT
Eric Van Cutsem, BE

ESMO PRECEPTORSHIP PROGRAMME COLORECTAL CANCER

Multidisciplinary management, standards of care
and future perspectives

Lugano, Switzerland
15-16 November 2019

CO-CHAIRS: Erika Martinelli, Italy
Eric Van Cutsem, Belgium

SPEAKERS: André D'Hoore, Belgium
Elleke Dresen, Belgium
Elena Élez, Spain
Cord Langner, Austria
Nicola Normanno, Italy
Elizabeth Smyth, United Kingdom
Alberto Sobrero, Italy

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histoprosthetic factors
- To learn about the management of patients after progression, side-effects of treatments and in special situations

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 15 November 2019

09:00-09:15 15'	Welcome and introduction	Erika Martinelli, IT Eric Van Cutsem, BE
09:15-11:05 110'	SESSION 1 Early colorectal cancer	Chair: Alberto Sobrero, IT
20'	The point of view of the pathologist - Quality and rules of a good pathology report - Histo-prognostic factors: Number of lymph nodes, neural/lymphatic invasion, lymphocytic infiltration, MSH expression	Cord Langner, AT
20'	Optimal loco-regional staging for rectal cancer	Elleke Dresen, BE
20'	State-of-the-art: Standard(s) of surgical practice for resectable rectal cancer (special issues on rectal cancer, laparoscopy, transanal TME and robotic-assisted surgery)	André D'Hoore, BE
20'	State-of-the-art: Standard(s) of care in pre-operative treatment for rectal cancer	Alberto Sobrero, IT
15'	The role of chemotherapy in localized rectal cancer	Erika Martinelli, IT
15'	Discussion	All
11:05-11:30	Coffee break	
11:30-13:20 110'	SESSION 2 Adjuvant settings of colon cancer	Chair: Erika Martinelli, IT
30'	RAS, BRAF: Microsatellite instability and other molecular markers – How useful are they? Pitfalls in diagnostic?	Cord Langner, AT
30'	Adjuvant treatment for colon cancer II and III	Alberto Sobrero, IT
20'	Adjuvant treatment for elderly patients: How to address it	Alberto Sobrero, IT
30'	Participants clinical case discussion (3x10')	Faculty
13:20-14:30	Lunch	
14:30-16:25 115'	SESSION 3 Metastatic colorectal cancer	Chair: Eric Van Cutsem, BE
40'	Review of the ESMO Consensus Conference on metastatic colorectal cancer - Basic strategies and groups (RASwt/mut, BRAF mut) - Chemotherapy and targeted agents in first line	Elena Élez, ES
30'	Oligometastatic colorectal cancer: What to know about and how to treat it	Erika Martinelli, IT
45'	Presentation of two challenging clinical cases and faculty discussion	Erika Martinelli, IT
16:25-17:00	Coffee break	

17:00-18:35 95'	SESSION 4 Metastatic colorectal cancer: Special clinical situations	Chair: Eric Van Cutsem, BE
35'	How to integrate surgery or locoregional treatments in the treatment of patients with liver-only metastatic disease and dealing with synchronous primary and liver metastases	André D'Hoore, BE
15'	How to deal with elderly and frail patients or individuals with comorbidities	Elena Élez, ES
15'	How to deal with patients with isolated peritoneal metastases	André D'Hoore, BE
30'	Participants clinical case discussion (3x10')	Faculty
19:30	Dinner	

Saturday, 16 November 2019

09:00-10:00 60'	SESSION 5 Metastatic colorectal cancer: Maintenance and further lines	Chair: Erika Martinelli, IT
20'	The role of maintenance treatment, appropriate endpoints according to ESMO Consensus	Erika Martinelli, IT
40'	What to do after first-line failure (the role of the second line treatment) - What to do in third-line	Eric Van Cutsem, BE
10:00-11:30 60'	SESSION 6 New molecular therapies	Chair: Erika Martinelli, IT
30'	Immunotherapy in lower gastrointestinal cancers	Elizabeth Smyth, UK
10:30-11:00	Coffee break	
30'	Implications of NGS and molecular testing beyond RAS, RAF and MSI	Nicola Normanno, IT
11:30-11:50 20'	SESSION 7 Anal canal tumours	Chair: Elena Élez, ES
20'	Standard of care for anal canal squamous carcinomas	Elena Élez, ES
11:50-12:20 30'	SESSION 8 Metastatic colorectal cancer: Case discussion	Chair: Eric Van Cutsem, BE
30'	Participants clinical case discussion (3x10')	Faculty
12:20-12:35 15'	Conclusion and farewell	Eric Van Cutsem, BE
12:35-13:35	Lunch	

Note: Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion